Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$71.5MCash on Hand
21mo Cash Runway
Follow BBTX by emailGet an email when BBTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BBTX, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Bambusa Therapeutics adopted an amended and restated certificate of incorporation and amended and restated bylaws effective November 2, 2026, in connection with completing its initial public offering. The full texts are filed as Exhibits 3.1 and 3.2. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1 · Recruiting · A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) Registry primary completion date, not a results date
Jan 2027 · Phase 1 · Recruiting · A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) Registry primary completion date, not a results date
Feb 2027 · Phase 1 · Recruiting · A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic… Registry primary completion date, not a results date
Dec 2027 · Phase 1 · Recruiting · A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
BBTX holds $71.5M in cash and short-term investments and burns about $10.2M/quarter from operations,
an estimated runway of 21 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:16 · Low
Cash runway 21 months +8
S-1 registration (Oct 2026) +8
Recent financing filings on SEC EDGAR:
Oct 30, 2026 · Underwritten offering, $169M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BBTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.